The generic name for Dabigatran is dabigatran etexilate [1]. Dabigatran etexilate is an oral anticoagulant that acts as a direct thrombin inhibitor [2].
When does dabigatran etexilate patent expiry?
The patent expiry for dabigatran etexilate varies by region. For instance, U.S. patents related to dabigatran etexilate have faced challenges and expirations [3]. Information on specific patent expiries and market exclusivity can be found on sites like DrugPatentWatch.com [4].
What is dabigatran etexilate used for?
Dabigatran etexilate is prescribed to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation [2]. It is also used to treat deep vein thrombosis (DVT) and pulmonary embolism (PE), and to prevent their recurrence [2].
How does dabigatran compare to other anticoagulants?
Dabigatran etexilate belongs to a class of drugs known as direct oral anticoagulants (DOACs) [5]. Other DOACs include rivaroxaban, apixaban, and edoxaban [5]. Unlike warfarin, a vitamin K antagonist, DOACs do not typically require routine blood monitoring [5]. Each DOAC has a different mechanism of action and dosing schedule, and the choice depends on individual patient factors and physician recommendations [5].
Who makes dabigatran?
Dabigatran etexilate is manufactured by Boehringer Ingelheim [1].
What are the risks of taking dabigatran?
The most significant risk associated with dabigatran etexilate is bleeding, which can occur in any part of the body and may be serious or fatal [2]. Other potential side effects include indigestion, stomach pain, and nausea [2]. Patients should discuss their complete medical history and any other medications they are taking with their healthcare provider before starting dabigatran etexilate [2].
Can dabigatran be reversed?
Yes, idarucizumab is a specific reversal agent for dabigatran etexilate. It is used in situations where rapid reversal of its anticoagulant effect is needed due to life-threatening or uncontrolled bleeding [6].
When did dabigatran etexilate receive FDA approval?
Dabigatran etexilate was approved by the U.S. Food and Drug Administration (FDA) in 2010 [7].
What is the difference between dabigatran and dabigatran etexilate?
Dabigatran etexilate is the prodrug form of dabigatran. After oral administration, dabigatran etexilate is absorbed and then rapidly converted to its active form, dabigatran, in the plasma and liver [8]. Dabigatran is the active anticoagulant [8].
What happens if I miss a dose of dabigatran?
If a dose of dabigatran etexilate is missed, it should be taken as soon as the patient remembers, unless it is already time for the next dose. Patients should not take a double dose to make up for a missed one. If a dose is missed and it is close to the time for the next scheduled dose, the patient should skip the missed dose and continue with their regular dosing schedule [2].
Sources:
[1] https://www.drugpatentwatch.com/drug/dabigatran-etexilate
[2] https://www.mayoclinic.org/drugs-supplements/dabigatran-oral-route/proper-use/drg-20071727
[3] https://www.drugpatentwatch.com/asset/dabigatran-etexilate-us-patent-litigation-and-patent-expiry-analysis
[4] https://www.drugpatentwatch.com/
[5] https://www.heart.org/en/health-topics/atrial-fibrillation/treatment-of-atrial-fibrillation/anticoagulant-therapy-for-atrial-fibrillation
[6] https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-12232015
[7] https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/dabigatran-etexilate-pradaxa-drug-safety-communications
[8] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3036148/